[ad_1]
The Wall Street Journal reported on Dec. 3 that a Pfizer Inc. spokesperson stated that the time taken to expand the raw materials supply chain was longer than expected. Also, the results of the clinical trials were published later than expected. The target for global vaccine shipments by the end of this year The 100 million doses were revised down to 50 million doses, and 1.3 billion doses are still expected to be shipped next year.
A whistleblower directly involved in the development of the Pfizer vaccine revealed that some initial batches of raw materials were not meeting standards and this issue has been resolved, but it is too late to reach this year’s estimated shipments. Pfizer has never produced a “messenger ribonucleic acid (mRNA)” vaccine in the past. Simultaneous “vaccine development and supply chain establishment” is an unprecedented practice.
Pfizer (PFE.US) opened higher and lower on the 3rd, fell 1.74% and closed at US $ 40.09, closing for the first time in 5 business days.
Pfizer’s German partner BioNTech fell 1.99% on Day 3 to close at $ 118.68. Pfizer and BioNTech continued to decline 0.42% and 1.25%, respectively, after the third trading day.
Pfizer: Outbreak Prevention Measures Can’t Be Loosen Immediately
The Associated Press reported on April 2 that Pfizer Chief Executive Officer Albert Bourla warned governments not to immediately relax epidemic prevention restrictions or reopen economic activities. He said he’s not far from getting back to normal life, but definitely not right now.
It is not clear whether the new corona vaccine developed by Pfizer / BioNTech can prevent vaccinators from transmitting the virus to others without symptoms. Other questions include: how long can the protection of the vaccine last and what is the impact on pregnant women and children under 12 years of age.
Older people appear to be less reactive to mRNA vaccines
According to data from the slide released on day 1, Sara Oliver, an epidemiological information service officer in the Division of Viral Diseases of the Centers for Disease Control and Prevention (CDC), pointed out at the meeting that the reactogenicity of older adults to mRNA vaccines appears to be low. There are no reactogenicity data for residents of long-term care facilities (LTCF).
CNBC reported that the CDC-affiliated “Vaccine Advisory Committee (ACIP)” received 13 votes in favor and 1 against on Day 1, suggesting that priority should be given to 21 million healthcare workers and 3 million residents of long-term care services to combat the new coronavirus. (Vaccine for COVID-19.
The Financial Times reported on Day 3 that Keipp Talbot, the only associate professor of medicine at Vanderbilt University to vote against, said in an interview on Day 2 that it could be a wrong decision to give residents of long-term care facilities Term a priority to administer the new corona vaccine due to the effect of the vaccine in this group of people. They are generally not good, in part because they tend to be weaker and have complications such as diabetes.
(This article has been reprinted with permission from MoneyDJ News; source of first image: shutterstock)
Other readings:
New knowledge of science and technology, always updated
[ad_2]
